Article
Impact of glycoprotein B genotype and naturally occurring ORF UL56 polymorphisms upon susceptibility of clinical human cytomegalovirus isolates to letermovir.
Antiviral research - 1 Aug 2016
Lischka Peter, Zhang Douglas, Holder Daniel, Zimmermann Holger
Abstract excerpt
Letermovir is a novel anti-HCMV drug in Phase III development that targets the UL56 subunit of the viral terminase complex. In immunocompromised patients four major glycoprotein B (gB) subtypes are known and may influence pathogenesis and thus disease outcomes. Using a panel of 74 letermovir-naïve, low-passage, clinical HCMV isolates, we examined the potential impact of i) gB genotype and ii) naturally occurring...
Topics
- Acetates
- Antiviral Agents
- Cytomegalovirus
- Cytomegalovirus Infections
- Drug Resistance, Viral
- Ganciclovir
- Genotype
- Humans
- Microbial Sensitivity Tests
- Mutation
- Polymorphism, Genetic
